Silence Therapeutics Stock Forecast, Price & News

+2.26 (+8.68 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,400 shs
Average Volume1,690 shs
Market Capitalization$843.47 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Silence Therapeutics logo

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.00 out of 5 stars

Medical Sector

1131st out of 2,099 stocks

Pharmaceutical Preparations Industry

516th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Silence Therapeutics (NASDAQ:SLN) Frequently Asked Questions

Is Silence Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Silence Therapeutics stock.
View analyst ratings for Silence Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Silence Therapeutics?

Wall Street analysts have given Silence Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Silence Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Silence Therapeutics?

Silence Therapeutics saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 3,000 shares, an increase of 66.7% from the May 13th total of 1,800 shares. Based on an average trading volume of 900 shares, the short-interest ratio is presently 3.3 days.
View Silence Therapeutics' Short Interest

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the following people:
  • Mr. Mark Andrew Rothera, Pres, CEO & Exec. Director (Age 58, Pay $734.75k)
  • Dr. Giles V. Campion M.D., Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director (Age 67, Pay $614.89k)
  • Mr. Craig A. Tooman M.B.A., MBA, Chief Financial Officer (Age 55)
  • Ms. Gem Gokmen Hopkins, Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin, Sr. VP, Gen. Counsel & Chief Patent Officer (Age 61)
  • Ms. Linnea Elrington, VP & Head of HR
  • Dr. John Strafford, VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff, Sr. VP & Head of Manufacturing
  • Dr. Eric Floyd, Sr. VP & Head of Global Regulatory Affairs (Age 58)
  • Dr. Marie Wikstrom Lindholm Ph.D., Sr. VP of Molecular Design

Who are some of Silence Therapeutics' key competitors?

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN."

Who are Silence Therapeutics' major shareholders?

Silence Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Lombard Odier Asset Management USA Corp (4.02%), BVF Inc. IL (2.24%), Morgan Stanley (0.03%) and SG Americas Securities LLC (0.02%).

Which institutional investors are buying Silence Therapeutics stock?

SLN stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Lombard Odier Asset Management USA Corp, Morgan Stanley, and SG Americas Securities LLC.

How do I buy shares of Silence Therapeutics?

Shares of SLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately $28.31.

How much money does Silence Therapeutics make?

Silence Therapeutics has a market capitalization of $843.47 million and generates $5.48 million in revenue each year. The company earns $-41,790,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Silence Therapeutics have?

Silence Therapeutics employs 65 workers across the globe.

What is Silence Therapeutics' official website?

The official website for Silence Therapeutics is

Where are Silence Therapeutics' headquarters?

Silence Therapeutics is headquartered at 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The company can be reached via phone at 44 20 3457 6900.

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.